复星集团(Fosun)计划大举进军欧洲，对奢侈品牌、小型科技公司和仿制药行业展开一系列投资。以销售收入衡量，复星是中国最大的民营企业。
复星集团董事长、中国最富有的人之一郭广昌向英国《金融时报》表示，该集团正"深入讨论"上述三个领域的多个潜在投资目标。"我们确实有几个已经非常深入的项目……复星将成为中国投资欧洲的先驱企业之一，"郭广昌称。他表示，复星的任何一笔投资都有可能高达20亿美元，尽管初始投资可能会限制在1亿欧元（合1.31亿美元）到2亿欧元之间。
一批中国大型工业企业正在考量欧洲市场，试图开拓利用其科技专业能力、高技能劳动力基础和西方品牌，将其引入中国市场。复星就是其中之一。
"许多中国企业和我们一起来到这里，了解如何在这里投资，"中国工经联(China Federation of Industrial Economics)副会长刘海燕上周在汉堡中欧经济峰会(Summit on Sino-European economic relations)间隙表示。
汉堡商会(Hamburg Chamber of Commerce)的数据显示，过去一年，中国企业在欧洲投资3亿欧元，尽管这个数字只是欧洲企业对华53亿欧元投资的零头。
郭广昌表示，复星关注于那些它能够协助其在中国扩张的企业，以及与复星国内业务相匹配的企业。复星去年的销售收入达到348.6亿元人民币（合52亿美元）。
该集团尤其关注服装与鞋履品牌的投资机会。
复星还计划将医药业务扩展至欧洲，在欧洲建立研发中心和分销渠道，并投资仿制药行业。
郭广昌表示，他希望这些举措以及可能成立的合资企业，能够加强集团的新药开发能力。
复星医药持有全球最大的药品销售商之一中国医药集团(Sinopharm) 49%的股份。复星认为中药具有巨大的出口潜力。
译者/管婧
http://www.ftchinese.com/story/001035814
Fosun, China's largest private conglomerate by sales, is planning a foray into Europe with a range of investments into luxury brands, small technology companies and the generic drugs sector.
Guo Guangchang, Fosun's chairman and one of China's richest men, told the Financial Times the group was in "deep discussions" with a number of possible targets in all three areas. "We do have several projects where we are very deep in the process ... Fosun will be one of the Chinese pioneers in investing in Europe," Mr Guo said. He said Fosun could invest up to $2bn in any single deal, although initial investments would probably be limited to between €100m ($131m) and €200m each.
Fosun is part of a wave of large Chinese industrial companies that are eyeing the European market to tap into the continent's technological expertise, its highly skilled labour base and as well as western brands to take to the Chinese market.
"A number of Chinese companies came with us to understand how they can invest here," Liu Haiyan, vice-chairman of the China Federation of Industrial Economics, said on the sidelines of the Summit on Sino-European economic relations in Hamburg last week.
In the past year Chinese companies have invested €300m in Europe, according to figures from the Hamburg Chamber of Commerce, though this is a fraction of the €5.3bn that European companies have invested in China.
Mr Guo said Fosun, which reported sales of Rmb34.86bn ($5.2bn) last year, was focusing on companies that it could help expand in China and that would fit with its domestic operations.
The group is looking in particular to buy clothes and shoe brands.
Fosun also aims to expand its pharmaceutical business into Europe by setting up research and development centres and distribution channels and by buying into the generic drugs sector.
Mr Guo said he hoped these steps, as well as possible joint ventures, would strengthen the group in the development of new drugs.
Fosun Pharma owns 49 per cent of Sinopharm, one of the world's largest drugs distributors and it sees great potential in exporting Chinese traditional herbal medicine.
没有评论:
发表评论